Yonsei Severance Hospital
Welcome,         Profile    Billing    Logout  
 132 Trials 
226 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Yong Sik
NCT04803266: Elective Internal Mammary Node Irradiation in Women With Node-positive Breast Cancer

Active, not recruiting
3
747
RoW
Internal mammary node irradiation, No internal mammary node irradiation
Yonsei University
Breast Neoplasms
02/23
02/23
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Recruiting
3
510
Europe, Canada, Japan, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
10/26
02/27
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NCT06677944: Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer

Recruiting
2
47
RoW
Preoperative PBI
Yonsei University
Breast Cancer, Ductal Carcinoma in Situ, Invasive Breast Cancer
10/25
10/26
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
09/25
NCT06207474: A Study on BReast Cancer Patient Care Using chAtbot and Video Education for Radiation Therapy (BRAVE)

Completed
N/A
148
RoW
Video + Chatbot, Video + Paper, Paper + Chatbot, Paper + Paper
Yonsei University
Breast Neoplasms
04/23
04/23
3STLIF, NCT04823858: 3Spine Lumbar Fusion Real World Evidence Study

Recruiting
N/A
200
US
Lumbar Interbody Fusion
3Spine, MCRA
Lumbar Spine Degeneration
05/24
08/26
SDM-ADOPT, NCT06618638: Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment

Recruiting
N/A
340
RoW
Shared decision making model, Usual Care
Seoul National University Hospital, Seoul National University, Hallym University Kangnam Sacred Heart Hospital, Kangbuk Samsung Hospital, Korea University Guro Hospital, Seoul National University Boramae Hospital, Asan Medical Center, InjeUniversityBusanPaikHospital, Chonnam National University Hospital, Keimyung University Dongsan Medical Center
ADPKD (autosomal Dominant Polycystic Kidney Disease)
09/26
09/26
TLIF, NCT04073563: Transforaminal Lumbar Interbody Fusion

Recruiting
N/A
1017
US, RoW
Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems
Medtronic Spinal and Biologics
Degenerative Disease of the Lumbosacral Spine
04/26
04/28
SABR-ROC, NCT05444270: Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer

Recruiting
N/A
270
RoW
Standard salvage therapy, Standard salvage therapy + SABR
Yonsei University
Recurrent Epithelial Ovarian Cancer
12/26
12/26
K-BIO, NCT03929887: KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Recruiting
N/A
3000
RoW
Kidney Biopsy
Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, KangWon National University Hospital, Keimyung University Dongsan Medical Center, SMG-SNU Boramae Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Ministry of Health & Welfare, Korea
Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy, Focal Segmental Glomerulosclerosis, Lupus Nephritis, Crescentic Glomerulonephritis
12/28
12/28
Kim, Jin Seok
KONCLUDE, NCT02843191: Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy

Active, not recruiting
3
358
RoW
Chemotherapy
Kyung Hee University Hospital at Gangdong, Korean Society of ColoProctology, Pharmbio Korea Inc., Samjin Pharmaceutical Co., Ltd., Boryung Pharmaceutical Co., Ltd, JW Pharmaceutical
Rectal Cancer
07/23
06/26
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/25
08/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
CLAUDIA, NCT05534087: Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

Recruiting
3
236
RoW
mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy
Seoul National University Hospital
Colon Cancer
09/28
09/30
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
NCT03597087: The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study

Not yet recruiting
2
289
RoW
Anesthesia before transurethral resection of the bladder tumor, Anesthesia
Seoul National University Hospital
Bladder Cancer
07/21
12/22
NaliCap, NCT04371224: (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

Recruiting
2
200
RoW
Irinotecan Liposomal Injection [Onivyde], nal-IRI, Capecitabine, xeloda, 5-fluorouracil, 5FU, Leucovorin, LV
Seoul National University Hospital
Pancreatic Cancer
12/24
12/25
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
LINKER-MM1, NCT03761108 / 2018-003188-78: Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Checkmark Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Checkmark Completion of enrollment of trial for r/r multiple myeloma
Dec 2022 - Dec 2022: Completion of enrollment of trial for r/r multiple myeloma
Checkmark Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2021
More
Recruiting
1/2
387
Europe, Japan, US, RoW
Linvoseltamab, REGN5458
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Multiple Myeloma
05/32
06/32
NCT04492033: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Terminated
1/2
41
RoW
CTX-009 (ABL001), Paclitaxel, Irinotecan
Handok Inc., Compass Therapeutics, ABL Bio, Inc.
P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
01/24
01/25
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
ACCENT, NCT05355298: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

Recruiting
1/2
62
RoW
AMP945 ascending doses, AMP945 RP2D
Amplia Therapeutics Limited
Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma
05/25
05/25
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
148
RoW
HM95573, cobimetinib, HM95573, cetuximab
Hanmi Pharmaceutical Company Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor
09/24
12/24
DREAMM 9, NCT04091126 / 2019-003047-30: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Checkmark From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Recruiting
1
144
Europe, Canada, US, RoW
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
11/24
06/25
DREAMM 13, NCT04398680: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

Recruiting
1
28
Europe, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
11/25
11/25
NCT04722705: Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention

Recruiting
N/A
30
RoW
fractional Er:YAG laser, Matrixell, Medro corp., Seoul, Korea, Intense pulse light, IPL (Ellipse Flex, DDD, Hoersholm, Denmark)
Hallym University Kangnam Sacred Heart Hospital
Intense Pulsed Light, Erbium-yttrium Aluminum Garnet Laser, Scar Prevention
11/21
11/21
NCT04337333: Two-in-one Covered and Uncovered Metal Stent

Recruiting
N/A
100
RoW
Two-in-one stent
Ajou University School of Medicine
Extrahepatic Bile Duct Cancer, Pancreatic Cancer, Lymph Node Metastases, Gallbladder Cancer
12/21
12/21
NCT04835467: First-In-Human Intracoronary OCT-FLIm In Patients Undergoing PCI

Completed
N/A
40
RoW
Dual-modal OCT-FLIm
Korea University Guro Hospital
Atherosclerosis Coronary Artery With Angina Pectoris, Atheroscleroses, Coronary, Atherosclerotic Plaque, Thin-cap fIbroatheroma, Atherosclerosis
08/22
10/23
VISION, NCT04151615: VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

Completed
N/A
203
RoW
Boryung Pharmaceutical Co., Ltd
Multiple Myeloma
01/23
01/23
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Approved for marketing
N/A
Europe, Canada, US, RoW
Olaratumab, LY3012207
Eli Lilly and Company
Soft Tissue Sarcoma
 
 
NCT04853511: Comprehensive Assessment of Interconnection Between Brain Emotional Activity and Coronary Plaque Instability

Recruiting
N/A
200
RoW
OCT-FLIM (optical coherence tomography-fluorescence life time), 18F-FDG-PET/CT (positron emission tomography-computed tomography)
Korea University Guro Hospital
Atherosclerosis, Coronary, Emotional Stress, Inflammation, Hematopoiesis, Atherosclerosis Coronary Artery With Angina Pectoris, Atheroma; Heart, Atherosclerosis, Acute Coronary Syndrome
12/23
12/24
Shim, Jae Yong
NCT04598191: Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery

Recruiting
N/A
100
RoW
Iloprost, Control (Normal saline)
Yonsei University
Coronary Artery Occlusive Disease
12/22
12/22
Kim, Seung Up
NCT04584242: Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Recruiting
4
40
RoW
gluconon tab 15mg, suganon tab 5mg
Yonsei University
Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
05/22
05/22
NCT05473806: Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Active, not recruiting
4
28
RoW
Pioglitazone 15 Mg Oral Tablet, Gluconon tablet 15mg, Evogliptin 5mg, SUGANON tablet 5mg
Seung Up Kim
Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2
01/23
02/23
NCT01561586: Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

Recruiting
3
374
RoW
Weekly cisplatin with RT, Cisplatin, Tri-weekly cisplatin with RT
Korea Cancer Center Hospital, Seoul National University Hospital, Asan Medical Center, Gangnam Severance Hospital
Cervical Cancer
03/20
03/23
ALSummit, NCT04745299: Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS

Active, not recruiting
3
115
RoW
Lenzumestrocel, Neuronata-R inj, Autologous Bone Marrow derived Mesenchymal Stem Cell, Riluzole, Rilutek, Placebo Comparator, Normal Saline Inj.
Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis
12/24
05/26
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT06493799: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Not yet recruiting
3
226
NA
LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
Green Cross Wellbeing
Chronic Liver Disease
12/25
12/25
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Recruiting
3
150
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
NCT05532124: Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Recruiting
2
49
RoW
LAENNEC (Human Placenta Hydrolysate), normal saline
Green Cross Wellbeing
Chronic Liver Disease
03/23
06/23
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NCT06249854: Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2
70
RoW
Bojungikki-tang(BJIKT), Buzhong Yiqi Decoction, Hochu-ekki-to, Pembrolizumab
Korea Institute of Oriental Medicine
Non-small Cell Lung Cancer
12/25
12/25
KEYNOTE-G08, NCT05824975: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US, RoW
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), ENHERTU®, pembrolizumab, KEYTRUDA®
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
11/25
04/27
NCT06676423: Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

Completed
1
8
RoW
Lenzumestrocel, Neuronata-R, Autologous Bone Marrow derived Mesenchymal Stem cell, Riluzole, Rilutek
Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis
11/23
11/23
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Recruiting
1
400
Europe, US, RoW
KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib
Pierre Fabre Medicament
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
12/24
12/25
NCT04801095: A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

Recruiting
1
100
RoW
WM-S1-030
Wellmarker Bio, Covance
Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Cholangiocarcinoma, Head and Neck Cancer
08/25
08/25
NCT04122833: Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Recruiting
N/A
80
RoW
Next generation sequencing
Konkuk University Medical Center, Roche Diagnostics, Foundation Medicine
Adenocarcinoma of Lung, EGFR Activating Mutation
09/23
12/24
NCT05736341: Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia

Completed
N/A
80
RoW
Remimazolam besylate, Midazolam
Yonsei University
Pregnancy, Cesarean Section, Spinal Anesthesia
05/23
01/24
NCT06327165: Predictability of ANI (Analgesia Nociception Index) for Spinal Hypotension

Recruiting
N/A
40
RoW
observation
Yonsei University
Cesarean Section, Spinal Anesthesia
12/24
12/24
NCT04615091: Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Recruiting
N/A
250
Europe, Canada, US, RoW
Azienda Ospedaliera Universitaria Integrata Verona
Advanced Chronic Liver Disease, Surgery--Complications
10/21
08/22
Kim, Deog Kyeom
NCT04913831: Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study

Recruiting
4
30
RoW
Cerebrolysin, Placebo
Yonsei University
Stroke
03/24
03/24
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
NCT04637737: Effect of Anterioposterior Weight Shifting Training With Visual Biofeedback in Subacute Stroke

Recruiting
N/A
50
RoW
anterioposterior Weight Shifting Training with Visual Biofeedback, Conventional therapy
Yonsei University
Stroke
06/21
06/21
NCT04651322: Quantified Analysis of Neuronal Recovery Using Myelin Imaging After Robot Assisted Upper Arm Training in Subacute Stroke Patients

Recruiting
N/A
24
RoW
upper robot Robot assisted upper arm training(RAT), Conventional therapy
Yonsei University
Stroke
06/21
06/21
NCT04649684: The Effectiveness of Exoskeleton Type Robotic Gait Training Using CIMT for Lower Extremity: in the Aspect of Gait Independence and Balance

Recruiting
N/A
40
RoW
Conventional robot-assisted gait training, Lower CIMT robot-assisted gait training group
Yonsei University
Acute Hemiplegic Stroke Including Subacute Phases
10/21
11/21
NCT04652128: Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke Patients

Recruiting
N/A
56
RoW
Zoledronic acid, Placebo
Yonsei University
Stroke
07/22
02/23
NCT04651335: Comparison of Concentric or Eccentric Virtual Reality Training Program in Subacute-stroke Patients With Hemispatial Neglect

Recruiting
N/A
44
RoW
afferent virtual reality program, efferent virtual reality program
Yonsei University
Stroke, Neglect
08/22
12/22
NCT04654793: The Effect of Robotics-assisted Tilt Table and Functional Electrical Stimulation in Stroke Patients

Recruiting
N/A
48
RoW
Robot assisted inclined bed treatment and FES, conventional inclined bed treatment
Yonsei University
Stroke
12/22
03/23
NCT05693233: Effect of Soft Robotic Exosuit Assistance in Healthy People

Recruiting
N/A
10
RoW
EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation
Yonsei University
Healthy Person
03/23
03/23
Kim, Hyun Soo
COALA, NCT05383183: Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

Recruiting
4
630
RoW
Choline Alfoscerate 400mg, Placebo
Daewoong Bio Inc.
Alzheimer Disease
06/25
12/25
NCT05803941: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Recruiting
4
700
Europe, Canada, US, RoW
AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617
Novartis Pharmaceuticals
Prostate Cancer
07/33
07/33
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
PROUD, NCT05666804: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Recruiting
3
160
RoW
Brolucizumab 6mg, Beovu
Novartis Pharmaceuticals
Macular Polypoidal Choroidal Vasculopathy (PCV)
09/25
09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
PRECISIONS, NCT04300920: Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection () Trial

Active, not recruiting
3
202
US
N-acetyl cysteine, NAC, Placebo
Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation
Idiopathic Pulmonary Fibrosis
02/26
02/26
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
NCT03132974: Evaluation of Efficacy and Safety of Single and Multiple Therapy of Herbal Medicine/Chuna Therapy on Non-specific Chronic Low Back Pain: A Study Protocol for Multicenter, 3-arm, Randomized, Single Blinded, Parallel Group, Incomplete Factorial Design, Pilot Study -

Recruiting
2/3
150
RoW
Sogyeonghwalhyeol-tang granule, Sogyeonghwalhyeol-tang granule with manipulation procedure, Placebo with manipulation procedure
Gachon University Gil Oriental Medical Hospital, Daejeon University, Semyung University Korean Medicine Hospital in Chungju, Woosuk University Oriental Medical Center
Chronic Low Back Pain
12/21
12/21
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Terminated
2
6
US
Y-90 TARE, Atezolizumab, Tecentriq, Bevacizumab, Avastin
Aiwu Ruth He, MD, Georgetown University, Genentech, Inc.
Hepatocellular Carcinoma
06/23
06/23
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Terminated
2
4
US
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Washington University School of Medicine, Viewray Inc.
Gastric Adenocarcinoma
12/23
11/24
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Recruiting
2
42
US
Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
06/27
06/28
NCT04166318: Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Recruiting
2
252
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Mitomycin, Ametycine, MITO, MITO-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
12/29
12/29
NCT02899091: Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease

Active, not recruiting
1/2
24
RoW
CB-AC-02, Placebo
CHABiotech CO., Ltd
Alzheimer's Disease
12/24
12/24
NCT05877430: Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Recruiting
1/2
160
US, RoW
CJRB-101, Pembrolizumab injection
CJ Bioscience, Inc.
NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
07/26
10/27
BET-PSMA-121, NCT05413850: Anti-tumour Activity of (177Lu) RhPSMA-10.1 Injection

Recruiting
1/2
150
Europe, US
177Lu-rhPSMA-10.1 injection, 177Lu-rhPSMA-10.1, 18F-rhPSMA-7.3 injection, 18F-rhPSMA-7.3
Blue Earth Therapeutics Ltd, PSI CRO
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, MCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases
08/26
10/26
NCT03516708: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Hourglass Jan 2019 - Jan 2019 : P1/2 trial in advanced rectal cancer
Recruiting
1/2
49
US
Epacadostat, INCB024360, Short-course radiation therapy, SCRT, CAPOX chemotherapy, FOLFOX chemotherapy
Washington University School of Medicine, Incyte Corporation, National Cancer Institute (NCI)
Rectal Cancer
07/27
08/30
NCT05039905: SLN Detection With Tc-MSA-ICG in Lung Cancer Patients

Recruiting
1
10
RoW
99mTc-MSA-ICG
Korea University Guro Hospital
Lung Cancer
12/21
12/21
NCT04046575: Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

Recruiting
1
20
US
Intensity Modulated Radiation Therapy, IMRT, Carboplatin, Paraplatin, MD Anderson Symptom Inventory (MDASI)-Plus module, EuroQol (EQ-5D), SF-12, MOS Social Support Measure, CES-D, Blood for ctDNA (optional), Blood for SCCA, Paclitaxel, Taxol
Washington University School of Medicine
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
09/25
09/27
NCT06167941: Identification of Integrin ab Expression in Lung Cancer Patients

Completed
N/A
61
RoW
Lung cancer types
Korea University Guro Hospital
Expression of Integrin ανβ3 in Lung Cancer
09/21
11/21
 

Download Options